Literature DB >> 12595612

Central nervous system involvement in the antiphospholipid (Hughes) syndrome.

G Sanna1, M L Bertolaccini, M J Cuadrado, M A Khamashta, G R V Hughes.   

Abstract

The antiphospholipid (Hughes) syndrome (APS) is characterized by arterial and/or venous thrombosis and pregnancy morbidity in the presence of anticardiolipin antibodies and/or lupus anticoagulant. APS can occur either as a primary disorder or secondary to a connective tissue disease, most frequently systemic lupus erythematosus. Central nervous system (CNS) involvement is one of the most prominent clinical manifestations of APS, and includes arterial and venous thrombotic events, psychiatric features and a variety of other non-thrombotic neurological syndromes. In this review we focus on the common and some of the less common CNS manifestations that have been reported in association with antiphospholipid antibodies.

Entities:  

Mesh:

Year:  2003        PMID: 12595612     DOI: 10.1093/rheumatology/keg080

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  39 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  Antiphospholipid syndrome and cognition.

Authors:  Bernardo Liberato; Roger A Levy
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

Review 3.  Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons.

Authors:  Eyal Muscal; Robin L Brey
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 4.  Autoantibodies involved in neuropsychiatric manifestations associated with systemic lupus erythematosus: a systematic review.

Authors:  Savino Sciascia; Maria Laura Bertolaccini; Dario Roccatello; Munther A Khamashta; Giovanni Sanna
Journal:  J Neurol       Date:  2014-06-21       Impact factor: 4.849

5.  Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.

Authors:  Melissa Padovan; Gabriella Castellino; Alessandra Bortoluzzi; Luisa Caniatti; Francesco Trotta; Marcello Govoni
Journal:  Rheumatol Int       Date:  2010-07-31       Impact factor: 2.631

6.  Deep brain reversible encephalopathy: association with secondary antiphospholipid antibody syndrome.

Authors:  T Parikh; K Shifteh; M L Lipton; J A Bello; A L Brook
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

Review 7.  Cognitive impairment in antiphospholipid syndrome: evidence from animal models.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Caio Rodrigues Guirau; Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2012-01-05       Impact factor: 2.980

8.  Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis.

Authors:  D Paran; J Chapman; A D Korczyn; O Elkayam; O Hilkevich; G B Groozman; D Levartovsky; I Litinsky; D Caspi; Y Segev; V E Drory
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

9.  Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis.

Authors:  Imad Uthman; Ismail Khalil; Raja Sawaya; Ali Taher
Journal:  Clin Rheumatol       Date:  2004-04-14       Impact factor: 2.980

10.  The challenges of antiphospholipid syndrome: experience from diagnosis to self-care.

Authors:  Kathryn Larmour; Gareth Lewis; Gary Benson; Jennifer Hanko
Journal:  BMJ Case Rep       Date:  2014-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.